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Background
DNA methyl transferase 1 (DNMT-1) is a key epigenetic
enzyme in cancer cells which inactivates proliferation
terminating genes and downregulates the expression of
cancer related proteins and neoantigens by hypermethyla-
tion. Prolonged exposure of tumor cells to DAC is
required for sufficient demethylation. Clinical use of deci-
tabine to target DNMT-1 is restricted by its short in vivo
half-life (about 10 minutes) due to rapid inactivation by
the enzyme cytidine deaminase (CDA) present in tissues.
Tetrahydrouridne(THU), an oral inhibitor of CDA can
overcome the pharmacokinetic (PK) limitation.
Hypothesis
Novel pharmacologic combination of THU with micro-
doses of DAC can significantly increase half-life of DAC
allowing sufficient interaction between DNMT-1 and deci-
tabine to overcome epigenetic repression by DNMT-1.
This could lead to enhanced expression of epigenetically
silenced cancer-related proteins and antigens, attracting a
robust immune response in the tumor milieu. Increased
lymphocytic infiltrate in the tumor post the immune prim-
ing by decitabine can augment response to immune check-
point inhibitor MPDL3280A, an anti PD-L1 antibody.
Study design
This is a proof-of-concept Phase II single arm open
label prospective clinical trial in patients with advanced
non-small cell lung cancer (NSCLC) with at least one
prior chemotherapy (Figure 1).
Methods
The study treatment would be DAC 0.002 mg/m2 and
THU at a dose of 400 mg/m2 at a fixed dose administered
orally 2X/week for 8 weeks followed by treatment with
1200mg MPDL3280A every 3 weeks until progression.
The THU-DAC regimen for immune priming is selected
based on ongoing Phase I clinical trial in nonmalignant
disease, and IND enabling GLP toxicology studies.
Doubling in the number of activated TILs in the tumor
compared to pre-treatment biopsy will be considered
evidence of immune induction by DAC. The trial will be
conducted in two stages. The first stage will be an assess-
ment of the immunologic effect of the combination. The
second stage, which will occur only if THU-DAC is shown
to have a significant priming effect, will assess the ability
of the immunologic response to translate to clinical effi-
cacy. Based on our previous studies we anticipate
in advanced stage NSCLC approximately 25% patients will
have high TILs and hypothesize that THU-DAC will
increase that proportion to >50%. With 24 patients there
will be at least 90% power to detect such a difference.
Assuming the combination does indeed prime the
immune system, stage 2 will be implemented and a two-
stage accrual design will be used to assess clinical efficacy,
with the 24 patients already accrued.
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